Pregenen grants Cellectis an option to license exclusive rights to genome engineering technology, such as meganucleases and meganuclease vector technology discovered by the partners

Pregenen Inc.

U.S. / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Cellectis S.A.

France / Small-Cap Biopharma (<$1 billion)

$133.7m on 06/24/2011 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced